DSMC recommends continuation of MacroGenics' Phase III of margetuximab to treat breast cancer

MacroGenics Inc. (NASDAQ:MGNX) said an independent DSMC recommended continuation of the Phase III SOPHIA trial of margetuximab (MGAH22) to treat

Read the full 202 word article

User Sign In